Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Not applicable

Comparison of Erector Spinae Plane Block (ESPB) With the Combination of Superficial Parasternal Intercostal Plane Block (SPIPB) and Serratus Anterior Plane Block (SAPB) in the Management of Postoperative Sternotomy Pain in Patients Undergoing Cardiac Surgery Via Sternotomy

NCT07472296 · tracked via the Priya Life Science Turkey tracker
Phase
Not applicable
Started
2025-11-01
Last updated
2026-03-16

Condition(s) studied

Postoperative PainSternotomy PainAcute PainCardiac SurgeryPain Management

Investigational drug(s) / intervention(s)

Erector spinae plane block (ESPB)Superficial Parasternal Intercostal Plane Block (SPIPB)Serratus Anterior Plane Block (SAPB)

Erector spinae plane block (ESPB): Bilateral ultrasound-guided ESPB is performed at the T4 or T5 vertebral level. Following skin preparation and visualization of the transverse process and erector spinae muscle, a block needle is inserted. After confirming the needle tip position between the muscle and the transverse process, 0.5 mL/kg of 0.25% Bupivacaine is injected on each side.

Superficial Parasternal Intercostal Plane Block (SPIPB): Bilateral ultrasound-guided SPIPB is performed. 0.25% Bupivacaine is administered. This is part of a combined regional analgesia technique for sternotomy.

Serratus Anterior Plane Block (SAPB): Bilateral ultrasound-guided SAPB is performed. 0.25% Bupivacaine is administered. This is part of a combined regional analgesia technique for the chest wall.

Study summary

This study aims to compare the effectiveness of two regional anesthesia techniques in managing pain for participants undergoing cardiac surgery via sternotomy. The investigators will evaluate whether the Erector Spinae Plane Block (ESPB) or a combination of the Superficial Parasternal Intercostal Plane Block (SPIPB) and Serratus Anterior Plane Block (SAPB) provides better pain control and recovery outcomes.

Eligibility

Sex
ALL
Min age
18 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria: * Patients aged between 18 and 80 years. * Patients classified as American Society of Anesthesiologists (ASA) physical status I, II, or III. * Patients scheduled for elective cardiac surgery via median sternotomy. * Patients who have provided written informed consent. Exclusion Criteria: * Pregnancy or suspected pregnancy. * Body Mass Index (BMI) \> 35 kg/m². * Known allergy or hypersensitivity to local anesthetics (e.g., bupivacaine). * Suspected coagulopathy or bleeding disorders. * Infection at the site of the regional block injection. * Severe hepatic or renal failure. * Severe neurological or psychiatric disorders. * Emergency surgical procedures. * Re-operation cases (Redo-surgery)

Primary outcome measure(s)

  • Pain Intensity (Visual Analog Scale Score) — At 0, 1, 2, 4, 8, 12, 16 and 24 hours postoperatively.
    Pain levels assessed using the Visual Analog Scale (0 = no pain, 10 = worst imaginable pain).

Trial sites (1)

FacilityCityRegionStatus
Bursa Uludag University Hospital Bursa Nilüfer Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07472296 on ClinicalTrials.gov ↗ ← All trials in Turkey